ENTERO VU 24% Oral suspension Ref.[50368] Active ingredients: Barium sulfate

Source: FDA, National Drug Code (US)  Revision Year: 2022 

1. Indications and Usage

ENTERO VU 24% is indicated for use in small bowel radiographic examinations to visualize the gastrointestinal (GI) tract in adult patients.

2. Dosage and Administration

2.1 Recommended Dosing

  • The recommended oral dose of ENTERO VU 24% is:
    • Adults: 600 mL

2.2 Administration Instructions

  • For oral use only
  • Shake bottle vigorously prior to oral administration to fully suspend product
  • Administer undiluted
  • Discard any unused suspension
  • Advise patients to hydrate following the barium sulfate procedure
  • Advise patient at risk for constipation or delayed gastrointestinal transit to monitor for worsening of their condition after administration of barium sulfate and seek medical attention if worsening and advise using laxatives to enhance gastrointestinal transit.

16.2. Storage and Handling

Store at USP controlled room temperature 20°C to 25°C (68°F to 77° F). Protect from freezing.

< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈